This study addresses these challenges by developing a MNEV for NSCLC, using reverse vaccinology and bioinformatics to identify and design neoantigens that elicit robust B-cell, CD4+, and CD8+ T-cell responses. This evidence concerns the gene CD4 and non-small cell lung carcinoma.